Nuveen LLC Makes New $243,000 Investment in Corbus Pharmaceuticals Holdings, Inc. $CRBP

Nuveen LLC bought a new position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) in the 1st quarter, Holdings Channel.com reports. The institutional investor bought 45,689 shares of the biopharmaceutical company’s stock, valued at approximately $243,000.

Other large investors have also bought and sold shares of the company. Two Sigma Investments LP raised its holdings in Corbus Pharmaceuticals by 212.3% in the fourth quarter. Two Sigma Investments LP now owns 134,175 shares of the biopharmaceutical company’s stock worth $1,583,000 after buying an additional 91,205 shares during the last quarter. Millennium Management LLC raised its holdings in Corbus Pharmaceuticals by 215.0% in the fourth quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company’s stock worth $4,563,000 after buying an additional 263,902 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Corbus Pharmaceuticals by 46.8% during the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 2,616 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Corbus Pharmaceuticals during the fourth quarter valued at approximately $323,000. Finally, Northern Trust Corp raised its holdings in shares of Corbus Pharmaceuticals by 12.4% during the fourth quarter. Northern Trust Corp now owns 103,264 shares of the biopharmaceutical company’s stock valued at $1,219,000 after purchasing an additional 11,400 shares during the last quarter. 64.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CRBP shares. Oppenheimer decreased their price objective on shares of Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating for the company in a report on Wednesday, August 6th. Lifesci Capital raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a report on Saturday, July 12th. Finally, B. Riley raised shares of Corbus Pharmaceuticals to a “strong-buy” rating and set a $28.00 price objective for the company in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company’s stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has an average rating of “Buy” and an average target price of $49.00.

Corbus Pharmaceuticals Trading Down 1.6%

Shares of CRBP stock opened at $9.86 on Friday. Corbus Pharmaceuticals Holdings, Inc. has a 12 month low of $4.64 and a 12 month high of $56.93. The stock has a market cap of $120.88 million, a P/E ratio of -2.07 and a beta of 3.08. The company has a 50 day simple moving average of $8.93 and a two-hundred day simple moving average of $7.71.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.11. As a group, equities analysts forecast that Corbus Pharmaceuticals Holdings, Inc. will post -4.23 earnings per share for the current year.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.